Close Menu

NEW YORK – Investment bank Piper Jaffray today upgraded shares of Pacific Biosciences to Overweight after conducting checks on placements of the firm's Sequel II single-molecule sequencing instrument.

Piper Jaffray analyst William Quirk wrote in a note to investors that the bank's channel checks imply 36 to 42 placements of the Sequel II, which launched earlier this year, in the third quarter. He noted that PacBio had placed 41 Sequel II instruments through the second quarter of 2019, which was above his expectations of around 25.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.

A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.

NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.

In Nature this week: epigenetic factors that prevent healthy aging and more.

Sponsored by

This webinar will discuss data from a recent real-world comparison study evaluating performance of two cell-free DNA methodologies as first-line prenatal screens.

Sponsored by

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.